News

Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat
Madrigal Pharmaceuticals (MDGL) stock gains as the company's Q2 2025 results exceed expectations with a 15-fold surge in ...
Epstein's ex, Ghislaine Maxwell, doesn't want grand jury transcripts released
Jeffrey Epstein’s ex-girlfriend wants to keep grand jury records secret in the sex trafficking case that sent her to prison.
Zacks Investment Research on MSN7h
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $1.9 per share versus the Zacks Consensus Estimate of a loss of $3.48. This compares to a loss of $7.1 per share a year ago. These figures are ...
Madrigal: Q2 Earnings Snapshot
WEST CONSHOHOCKEN, Pa. (AP) — WEST CONSHOHOCKEN, Pa. (AP) — Madrigal Pharmaceuticals Inc. (MDGL) on Tuesday reported a loss of $42.3 million in its second quarter. The West Conshohocken, ...
MyChesCo on MSN3d
Madrigal Licenses Oral GLP-1 Drug From CSPC, Targets Next-Gen MASH Therapy
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) announced Monday it has secured exclusive global rights to develop ...
BioPharma Dive6d
Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval
Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA ...
Madrigal signs potential $2 billion-plus deal with China's CSPC to develop liver drug
U.S. drugmaker Madrigal Pharmaceuticals has struck a licensing deal with CSPC Pharmaceutical Group that could be worth more than $2 billion for the Chinese company if it results in a new drug for a ...